Assessment of the association between mixed‐oil lipid injectable emulsion use and 30‐day mortality or infection persistence from fungal catheter‐related bloodstream infections in pediatric patients following receipt of parenteral nutrition: A retrospective cohort study
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025
DOI: 10.1002/phar.70037 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2025. Verfasst von Gustavo R Alvira-Arill und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, Medical University of South Carolina, Charleston, South Carolina, USA. Hauptthemen laut MEDLINE: Parenteral Nutrition, Catheter-Related Infections, Fat Emulsions, Intravenous. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, ACCP Foundation, University of Tennessee Health Science Center College of Pharmacy.
Abstract (Originalsprache)
Background
Compared to soybean‐oil and fish‐oil formulations, the use of mixed‐oil lipid injectable emulsion is associated with reduced catheter‐related bloodstream infection rates in pediatric patients receiving parenteral nutrition. The objective of this study was to compare clinical outcomes of fungal catheter‐related bloodstream infections in pediatric patients following receipt of parenteral nutrition with mixed‐oil (SMOFlipid) lipid injectable emulsion or other formulations (soybean‐oil [Intralipid] or fish‐oil [Omegaven]).
Methods
A retrospective cohort study of pediatric patients with fungal catheter‐related bloodstream infections following administration of parenteral nutrition and injectable lipid emulsion from five pediatric hospitals in the United States during a 5‐year period was conducted. Differences in a composite outcome of 30‐day mortality from first positive blood culture and/or infection persistence based on type of lipid injectable emulsion received prior to infection were assessed through generalized linear mixed models with binomial distribution.
Results
One‐hundred twelve fungal catheter‐related bloodstream infections were assessed from 104 patients who received mixed‐oil lipid injectable emulsion ( n = 43) or other formulations ( n = 69) prior to infection. Thirty‐nine infections met the composite outcome (32 with persistent infection, three with 30‐day mortality, and four with both). On multivariable analysis, receipt of mixed‐oil lipid injectable emulsion demonstrated a non‐statistically significant increase in the composite outcome (odds ratio [OR] [95% confidence interval {CI}]: 1.80 [0.75–4.34]; p = 0.19). Factors independently associated with the composite outcome include receipt of systemic antifungal prophylaxis (OR [95% CI]: 5.72 [1.33–24.7]; p = 0.019) and delay in central venous catheter removal (OR [95% CI]: 1.09 [1.01–1.19]; p = 0.03). Notable factors not associated with the composite outcome included continued receipt of lipid injectable emulsion, empiric antifungal choice, time to antifungal administration, and gastrointestinal surgery within 90 days prior to infection.
Conclusion
Use of mixed‐oil lipid injectable emulsion compared to other formulations (soybean‐oil or fish‐oil) demonstrated a non‐statistically significant increase in 30‐day mortality and/or infection persistence from fungal catheter‐related bloodstream infections in pediatric patients receiving parenteral nutrition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, Medical University of South Carolina, Charleston, South Carolina, USA.
- Department of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Nashville and Memphis, Tennessee, USA.
- Department of Pharmacy, Le Bonheur Children's Hospital, Memphis, Tennessee, USA.
- Department of Pharmacy, Children's of Alabama, Birmingham, Alabama, USA.
- Department of Pharmacy, Nationwide Children's Hospital, Columbus, Ohio, USA.
- Department of Pharmacy Practice, School of Pharmacy, Loma Linda University, Loma Linda, California, USA.
ORCID-Profile: Gustavo R Alvira-Arill, Brian M Peters
Förderung
- NIAID NIH HHS
- ACCP Foundation
- University of Tennessee Health Science Center College of Pharmacy
- National Institute of Allergy and Infectious Diseases (JSS and BMP)
- College of Pharmacy, Health Science Center, University of Tennessee
Zitieren
APA
Alvira-Arill, G. R., Yarbrough, A., Tansmore, J., Sierra, C. M., Bashqoy, F., Herrera, O. R., Peters, B. M., & Stultz, J. S. (2025). Assessment of the association between mixed‐oil lipid injectable emulsion use and 30‐day mortality or infection persistence from fungal catheter‐related bloodstream infections in pediatric patients following receipt of parenteral nutrition: A retrospective cohort study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70037
Vancouver
Alvira-Arill GR, Yarbrough A, Tansmore J, Sierra CM, Bashqoy F, Herrera OR, et al. Assessment of the association between mixed‐oil lipid injectable emulsion use and 30‐day mortality or infection persistence from fungal catheter‐related bloodstream infections in pediatric patients following receipt of parenteral nutrition: A retrospective cohort study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025. doi:10.1002/phar.70037
BibTeX
@article{AlviraArill2025,
author = {Alvira-Arill, Gustavo R and Yarbrough, April and Tansmore, Jessica and Sierra, Caroline M and Bashqoy, Ferras and Herrera, Oscar R and Peters, Brian M and Stultz, Jeremy S},
title = {Assessment of the association between mixed‐oil lipid injectable emulsion use and 30‐day mortality or infection persistence from fungal catheter‐related bloodstream infections in pediatric patients following receipt of parenteral nutrition: A retrospective cohort study},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2025},
doi = {10.1002/phar.70037}
}
EUVIMED